Skip to content

Evaluation of different dental implants based on their stability and their impact on the body s natural defense system.

A split mouth randomized controlled trial comparing implant stability and defense regulatory peptide levels in two different implant designs - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084905
Enrollment
28
Registered
2025-04-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K084- Partial loss of teeth

Interventions

Intervention1: Buttress Thread Design Implants: Implant stability measurement at 3rd, 6th, and 12th month follow-up. LL-37, the defense regulatory peptide level will be also evaluated at 3rd and 6th m

Sponsors

Dr Ankeet Niwesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged 18-65 years, Patient with bilateral single missing teeth in posterior mandibular arch, Patients with good oral hygiene, Patients with adequate bone height and width to accommodate implant of appropriate dimension Co-operative patient, willing to give consent

Exclusion criteria

Exclusion criteria: Patients with ongoing periodontal disease or active oral infections , Patients with a known history of psoriasis, oral lichen planus, rheumatoid arthritis, or oral squamous cell carcinoma. Patients with a history of smoking, Patients with history of radiotherapy

Design outcomes

Primary

MeasureTime frame
To evaluate and compare the implant stability of two different implant designs at baseline and at the 3rd, 6th, and 12th months using resonance frequency analysis (RFA). To assess the levels of LL-37, a defense regulatory peptide, in peri-implant crevicular fluid (PICF) associated with different implant designs at baseline, 3rd month, and 6th month. Timepoint: Implant stability measurement at 3rd, 6th and 12th month follow up LL-37, the defense regulatory peptide level will be also evaluated at 3rd and 6th month

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Ankeet Niwesh

Manav Rachna International Institute of Research and Studies

nehajain.sds@mrei.ac.in9818095331

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026